Recorded live from the Wisconsin ADRC’s Alzheimer’s Disease & Related Dementias Research Day, Dr. Nathaniel Chin discusses the importance of mentorship and the future of neuroscience and Alzheimer’s disease research with the Alzheimer’s Association International Conference® (AAIC) Neuroscience Next 'One to Watch' award recipients and the event’s organizers.

Guests: Barbara Bendlin, PhD, director, UW-Madison Neuroscience and Public Policy Program, leader, Research Education Component (REC), Wisconsin Alzheimer’s Disease Research Center; Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer’s Association; Nadia Dehghani, BS, co-chair, Neuroscience Next Scientific Program Committee; Claire André, PhD, postdoctoral fellow, Center for Advanced Research in Sleep Medicine, Université de Montréal; Chinmayi Balusu, founder, CEO, Simply Neuroscience; Kacie Deters, PhD, assistant professor, University of California Los Angeles; Kao Lee Yang, MPA/PhD candidate in the Neuroscience and Public Policy Program, University of Wisconsin–Madison

Learn more about Dr. Barbara Bendlin at her bio on our website.

Learn more about Dr. Claire Sexton at her bio on the Alzheimer’s Association website.

Learn more about Nadia Dehghani at her bio on the Van Andel Institute website.

Learn more about Dr. Claire André, Chinmayi Balusu, Dr. Kacie Deters, and Kao Lee Yang at the press release, “Up-And-Coming Neuroscientists and Mentors Honored at Alzheimer’s Association International Conference Neuroscience Next,” on the Alzheimer’s Association website.

Learn more about Chinmayi Balusu’s company, Simply Neuroscience, on their website.

Learn more about AAIC Neuroscience Next at the Alzheimer’s Association website.

Learn more about Alzheimer’s Disease & Related Dementias Research Day on the Wisconsin Alzheimer’s Disease Research Center’s website.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Natascha Merten joins the podcast to discuss her study focused on trends in cognitive function across generations. Merten also explains her research on the associations between sensory and motor functions and blood-based biomarkers for neurodegeneration and dementia.

Guest: Natascha Merten, PhD, MS, director, Beaver Dam Offspring Study-Neurocognitive Aging Study, assistant professor, Departments of Population Health Sciences and Medicine, University of Wisconsin–Madison

Read Dr. Merten’s studies, “Better cognitive function in younger generations - Insights from two cohort studies of middle-aged to older adults in Wisconsin,” and “Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife,” through ScienceDirect.

Read Dr. Merten’s abstract from the 2022 Alzheimer’s Association’s International Conference through the journal Alzheimer’s & Dementia.

Read about Dr. Merten’s R01 grant, “Dr. Natascha Merten Awarded NIA Funding To Study Sensory Changes Associated With Cognitive Change” on our website.

Learn more about Dr. Merten in her bio on the University of Wisconsin Population Health Sciences website and on her Twitter @NataschaMerten.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Annalise Rahman-Filipiak joins the podcast to discuss her research focused on disclosing neuroimaging biomarkers across diverse populations. She addresses why some people might want to know their biomarker results, while others might not, and how careful disclosure of these results to at-risk individuals may help prepare them and their families for the future through personalized treatment, research engagement, advanced planning and emotional support.

Guest: Annalise Rahman-Filipiak, PhD, assistant professor, neuropsychologist, department of psychiatry, University of Michigan

Learn more about Dr. Rahman-Filipiak on the University of Michigan’s website.

Read Dr. Rahman-Filipiak’s article, “Interest in and perceived benefits and risks of Alzheimer’s disease clinical and biomarker results disclosure among diverse participants and care partners,” at the journal Alzheimer’s & Dementia website.

Follow Dr. Rahman-Filipiak on Twitter @RahFlipPhD.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

For families and dementia care partners, palliative care can help improve the quality of life for their loved ones and themselves by addressing physical and emotional needs. However, starting conversations around end-of-life care and planning can be difficult. Dr. Elizabeth Bukowy joins the podcast to explain the difference between palliative and hospice care, share how families and care partners can start these challenging conversations, and discuss why these discussions are essential for quality of life.

Guest: Elizabeth Bukowy, DO, CMD, assistant professor, Medical College of Wisconsin Division of Geriatrics; medical director, Lutheran Home and Congregational Home

Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website.

Watch the full keynotes of the event on our YouTube channel. Watch the pre-conference workshop for new dementia care professionals on our YouTube channel. Dr. Bukowy’s keynote starts at 1:46:46 in the recording.

Learn more about Dr. Bukowy in her bio on Froedtert Hospital’s  website.

Learn more about palliative care from our past episode, “Palliative Care And Hospice Conversations For Dementia Patients, Families And Caregivers.”

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

When seeking medical information and treatment, different racial and ethnic groups may require specially tailored information to relate to, understand and apply to their own experiences. In this episode, Dr. Fayron Epps joins the podcast to talk about the unique experiences of African American caregivers and her lab's work to provide education and assistance to their needs. Epps seeks to promote quality of life for families affected by dementia through research, education and service. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Research and Related Dementias.

Guest: Fayron Epps, PhD, RN, FGSA, FAAN, assistant professor, Nell Hodgson Woodruff School of Nursing, Emory University, principal investigator, Faith Village Research Lab, founder, Alter

Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website.

Watch the full keynotes of the event on our YouTube channel. Dr. Epps’ keynote starts at 1:13:37 in the recording.

Learn more about Dr. Epps on Alter’s website.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Mild cognitive impairment (MCI) is an emerging term in the field of Alzheimer’s disease and related dementias, characterized as the stage between the expected decline in memory and thinking that happens with age and the more severe decline of dementia. In this episode, Dr. Ronald Petersen joins the podcast to talk about how MCI compares to dementia, its many causes, and the impact of new lifestyle and drug interventions on its progression, as well as how his career led him to study Alzheimer's disease and MCI. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Disease and Related Dementias.

Guest: Ronald C. Petersen, MD, PhD, director, Mayo Clinic Alzheimer's Disease Research Center, director, Mayo Clinic Study of Aging, Cora Kanow Professor of Alzheimer’s Disease Research, Mayo Clinic College of Medicine

Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website.

Watch the full keynotes of the event on our YouTube channel. Dr. Petersen’s keynote starts at 22:12 in the recording.

Learn more about Dr. Petersen in his bio on his website.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023.

Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute

This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on February 13, 2023. Watch the video interview with Drs. Carlsson and Johnson here.

In a previous episode of Dementia Matters, Dr. Chin gave a brief overview of lecanemab’s clinical trials. Listen to it on Spotify, Apple Podcasts, our website, or wherever you listen.

Read more about the AHEAD study and A4 study at their respective websites.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Former Governor of Wisconsin, Martin Schreiber, returns to Dementia Matters to discuss different methods for communicating with a loved one with Alzheimer’s disease, including therapeutic fibbing. Governor Schreiber has been a widely outspoken advocate for Alzheimer’s disease while caring for his late wife Elaine, who passed away from the disease in April of 2022. In this episode, he also talks about his book, My Two Elaines, where he opens up about his experience as a caregiver.

Guest: Martin Schreiber, Former Governor of Wisconsin (1977-1979), Former Lt. Governor of Wisconsin (1971-1977)

Learn more about Martin Schreiber and his book, My Two Elaines, at his website, or follow him on Facebook.

Listen to Governor Schreiber’s previous appearance on our website or wherever you get your podcasts. 

Find transcripts and more at our website.

Email Dementia Matters

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives.

Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council

Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website.

Learn more about Part the Cloud at their website.

Learn more about the Alzheimer's Association at their website.

Learn more about Dr. Pike in her bio on her website.

Learn more about Mr. Johns in his bio on his website.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release.

Read the FDA’s news release regarding lecanemab’s accelerated approval on their website.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.